Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Online Letters: Observations

New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis

  1. Cristina Hernández, MD, PHD1,2,
  2. Marta García-Ramírez, PHD1,2,
  3. Nuria Colomé, PHD3,
  4. Marta Villarroel, BSC1,2,
  5. Lidia Corraliza, BSC1,2,
  6. Luis García-Pacual, MD, PHD4,
  7. Joan Casado, MD, PHD5,
  8. Francesc Canals, PHD3 and
  9. Rafael Simó, MD, PHD1,2,6
  1. 1CIBERDEM (CIBER de Diabetes y Enfermedades Metabólicas Asociadas), Instituto de Salud Carlos III, Barcelona, Spain;
  2. 2Diabetes and Metabolism Research Unit, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain;
  3. 3Proteomics Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain;
  4. 4Ophthalmology Services, Hospital Mútua de Terrassa, Barcelona, Spain;
  5. 5Department of Endocrinology, Hospital Mútua de Terrassa, Barcelona, Spain;
  6. 6Universitat Autónoma de Barcelona, Barcelona, Spain.
  1. Corresponding author: Rafael Simó, rsimo{at}ir.vhebron.net.
  1. C.H. and M.G.-R. contributed equally to this work.

Diabetes Care 2010 Jul; 33(7): e92-e92. https://doi.org/10.2337/dc10-0232
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Diabetic macular edema (DME) is the main cause of visual impairment in diabetic patients. The aim of the present study was to explore the differential proteomic pattern of the vitreous fluid from DME patients by means of proteomic analysis. For this purpose, we used fluorescence-based difference gel electrophoresis (DIGE). This technique provides accurate quantitative comparisons, and we further optimized it in order to avoid potential confounding factors (1).

Samples of vitreous from eight type 2 diabetic patients (four with DME without proliferative diabetic retinopathy [PDR] and four with PDR without DME), and eight from nondiabetic subjects with idiopathic macular hole (control group) were selected from our vitreous bank for proteomic analysis.

The protocol for sample collection was approved by the Vall d'Hebron hospital ethics committee, and informed consent was obtained from the patients. The study was conducted in accordance with the principles of the Declaration of Helsinki. Sample preparations, along with the details of DIGE proteomic analysis, have been described elsewhere (1).

Approximately 1,300 protein spots were detected. By selecting an abundance ratio of 1.5-fold as the threshold for the study, at least 81 spots were differentially produced (P < 0.05) between any two of the three groups evaluated. Following matrix-assisted laser desorption ionization/mass spectrometry time-of-flight/time-of-flight analysis, we were able to identify 25 intravitreal proteins (data available from the author upon request). Four of these proteins were specifically associated with DME. This means that there were significant differences between DME versus control subjects and DME versus PDR. These proteins were hemopexin, beta crystalline S, clusterin, and transthyretin. Hemopexin abundance was significantly increased in the vitreous fluid of patients with DME in comparison with PDR and control subjects. By contrast, beta crystalline S, clusterin, and transthyretin were significantly lower in DME patients than in PDR patients and control subjects. In view of the current information, hemopexin and clusterin seem to be more directly related to the development of DME.

Hemopexin is the best-characterized permeability factor in steroid-sensitive nephrotic syndrome (2). T-cell–associated cytokines like tumor necrosis factor-α are able to enhance hemopexin production in mesangial cells in vitro, and this effect is prevented by corticosteroids (3). It should be noted that proinflammatory cytokines have been involved in the development of DME and, therefore, hemopexin might be a mediator of the disruption of the blood-retinal barrier.

Clusterin is associated with protection from apoptotic retinal cell death (4). Recently, Kim et al. (5) demonstrated that clusterin effectively inhibited vascular endothelial growth factor–induced hyperpermeability in human retinal microvascular endothelial cells and in retinal vessels from streptozotocin-induced diabetic mice. Since clusterin plays an essential role in restoring tight junctions and limiting the inflammatory response after injury (two capital features in the pathogenesis of DME), it seems reasonable to propose clusterin deficit as a contributor to DME development.

In summary, we have shown that two-dimensional DIGE analysis facilitates the identification of new potential candidates involved in the development of DME. Further studies addressed to the evaluation of the precise role of these candidates in the pathogenesis of DME and their potential as therapeutic targets would appear to be warranted.

Acknowledgments

This study was supported by grants from the Ministerio de Ciencia e Innovación (SAF2009-07408) and from CIBERDEM (CIBER de Diabetes y Enfermedades Metabólicas Asociadas). CIBERDEM is an initiative of the Instituto de Salud Carlos III.

No potential conflicts of interest relevant to this article were reported.

  • © 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. García-Ramírez M,
    2. Canals F,
    3. Hernández C,
    4. Colomé N,
    5. Ferrer C,
    6. Carrasco E,
    7. García-Arumí J,
    8. Simó R
    : Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007; 50: 1294–1303
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Cheung PK,
    2. Klok PA,
    3. Baller JF,
    4. Bakker WW
    : Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 2000; 57: 1512–1520
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kapojos JJ,
    2. van den Berg A,
    3. van Goor H,
    4. te Loo MW,
    5. Poelstra K,
    6. Borghuis T,
    7. Bakker WW
    : Production of hemopexin by TNF-alpha stimulated human mesangial cells. Kidney Int 2003; 63: 1681–1686
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kim JH,
    2. Kim JH,
    3. Yu YS,
    4. Min BH,
    5. Kim KW
    : The role of clusterin in retinal development and free radical damage. Br J Ophthalmol 2007; 91: 1541–1546
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kim JH,
    2. Kim JH,
    3. Yu YS,
    4. Min BH,
    5. Kim KW
    : Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 1659–1665
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes Care: 33 (7)

In this Issue

July 2010, 33(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis
Cristina Hernández, Marta García-Ramírez, Nuria Colomé, Marta Villarroel, Lidia Corraliza, Luis García-Pacual, Joan Casado, Francesc Canals, Rafael Simó
Diabetes Care Jul 2010, 33 (7) e92; DOI: 10.2337/dc10-0232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis
Cristina Hernández, Marta García-Ramírez, Nuria Colomé, Marta Villarroel, Lidia Corraliza, Luis García-Pacual, Joan Casado, Francesc Canals, Rafael Simó
Diabetes Care Jul 2010, 33 (7) e92; DOI: 10.2337/dc10-0232
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence in Long-standing Type 1 Diabetes
  • FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
  • Diabetic Charcot Neuroarthropathy of the Hand: Clinical Course, Diagnosis, and Treatment Options
Show more Online Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.